Clinical trials, including Phase II and Phase III studies, have shown that sarilumab is effective across various RA patient groups, including those with an inadequate response to methotrexate (MTX) and those who failed TNF inhibitors. This evidence concerns the gene TNF and rheumatoid arthritis.